Trial Profile
A phase II randomized, observer-blind, active-controlled study to evaluate the immunogenicity and safety of a single dose of BioNet-Asiaâ??s acellular pertussis-only vaccine and its combined tetanus-diphtheria-acellular pertussis vaccine at multiple
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Diphtheria tetanus acellular pertussis vaccine-Bionet-Asia (Primary) ; DTaP vaccine (Primary)
- Indications Pertussis
- Focus Pharmacodynamics
- Sponsors BioNet-Asia
- 06 Dec 2023 Results assessing the efficacy maternal antibody transfer and safety data in mothers and neonates immunization with different doses of recombinant pertussis-containing vaccines, published in the Vaccine.
- 15 Jun 2023 Results published in the Vaccine
- 09 Apr 2019 Status changed from not yet recruiting to recruiting.